.png){kind=logo}
Science The evidence layer
The biology changed. So did the evidence.
You did the reading before you came here. You know what GLP-1 does, and you’ve learned to be wary of any practice that explains less than you already understand. This page is the part of Weightstry written for that — not a pitch, but the mechanism, the trials, and the limits, in the order a clinician would want to see them. Because the body that stopped responding to your old protocols is a different endocrine system than the one those protocols were built for.
A note on order, since it’s doing real work here: the medication most of the category leads with — the GLP-1 — is the third layer of this protocol, not the first thing we’ll tell you about. The deeper restoration is hormonal. We’ve arranged the evidence the way the clinical reasoning actually runs.
Reviewed by Dr. Sergio Naccarato, MD
There is a specific moment this page is written for: the one where the thing that worked stops working, and no amount of doing it harder brings the old result back. The protocol that held your body for two decades — the deficit, the training block, the discipline you never had to think about — meets a body that has quietly stopped answering to it. Most women arrive having been told, by more than one clinician, that this is age, or stress, or something to accept. It is none of those. It is measurable.
Perimenopause is not a single event. It is a multi-system endocrine transition, and its defining feature is not decline but instability — estradiol does not glide downward, it swings erratically for years before it falls, and the swing is what the body cannot calibrate to. The SWAN cohort, which followed women across the menopausal transition, documented these estradiol and FSH trajectories directly12, alongside the body-composition and bone changes that track the final menstrual period rather than chronological age311. It is why two women the same age can be in entirely different physiologic states.
The clinical consequence is simple to state and easy to miss: an intervention calibrated to a 34-year-old’s hormonal environment is being applied to a 46-year-old’s, and the gap between them is the whole problem. The math did not change. The system running the math did. What follows is that system, event by event.
- 01
- 02
Muscle slips.3
Lean mass declines as fat gain accelerates
- 03
Fat redistributes.4
Visceral deposition rises — the midsection thickens
- 04
Cortisol climbs.5
HPA shift — cortisol rises, the daily rhythm flattens
- 05
Sleep fragments.6
Architecture disrupts — waking, night-sweat wakes
- 06
- 07
Appetite shifts.9
Estrogen–satiety signaling — mechanism, evidence emerging
- 08
Cognition wavers.10
Brain fog, word gaps — a dip that tends to rebound
- 09
Bone thins.11
Loss accelerates to ~2% / year at the spine near the FMP
Read together, these are not nine things going wrong with you. They are one transition, described precisely enough to be acted on.
The protocol has four layers — hormonal, testosterone where indicated, metabolic, and the measurement and human oversight that hold them together. They are not equal, and they are not in the order the category trained you to expect. The metabolic layer, the GLP-1, is real and evidenced — and it is the third thing here, not the first. The layer that returns the most is the one most telehealth practices will not reliably build: the hormonal one. (The fourth layer, measurement, is the section that follows.)
Layer 01 · The hormonal layer
Estradiol and progesterone, where the evidence is strongest.
The hormonal layer is transdermal estradiol paired with oral micronized progesterone for women with a uterus. We lead with it because it is where the evidence is most settled. The Menopause Society’s 2022 Hormone Therapy Position Statement is unambiguous on two points: hormone therapy is the most effective treatment for the vasomotor symptoms — the hot flashes and night sweats of event 06 — and the genitourinary syndrome of menopause, and it prevents the bone loss of event 091213. Those are the proven wins. We name them as exactly that, and not more.
Sleep is the layer’s quietest effect, and worth stating carefully: relief of night sweats reduces the nighttime waking they cause — a different and more defensible claim than “hormone therapy fixes sleep.” What members frequently describe beyond that — steadier energy, a mind that feels less effortful by mid-afternoon — we treat as reported experience downstream of symptom and sleep relief, not as a proven cognitive or energy effect. The distinction matters to us because it should matter to you.
The benefit-risk calculus is favorable, with a specific and non-negotiable boundary: for women under 60, or within ten years of menopause, without contraindications. This is the timing hypothesis, and it is not a marketing line — it is the throughline of the age-stratified WHI re-analysis and the ELITE and KEEPS trials14151617, which is why the same therapy that read as risky in the original 2002 reporting reads as favorable once initiation timing is accounted for. Outside that window the conversation changes, and we have it honestly.
That correction is no longer only academic. The FDA has initiated removal of the broad boxed warnings on menopausal hormone therapy — cardiovascular disease, breast cancer, probable dementia — citing the original study’s limitations: an average participant age of 63, more than a decade past the average age of menopause, and a formulation no longer in common use2930. One boundary stays, and we state it: the endometrial-cancer warning for systemic estrogen-alone products remains, which is one reason progesterone is part of the protocol for women with a uterus. The regulator corrected the warning; it did not declare the question closed — and neither do we. Your risk picture is read individually, every time.
On formulation: the choice of transdermal estradiol and micronized progesterone is deliberate and evidence-led. Observational evidence — the ESTHER study on transdermal estradiol and venous thromboembolism, and the E3N cohort on micronized progesterone versus synthetic progestins1819 — is associated with a more favorable risk profile than the oral-estrogen-plus-synthetic-progestin combinations that shaped the older alarm. Observational is the honest word for that evidence, and we use it.
Layer 02 · Testosterone, precisely
The layer telehealth skips — scoped to one indication.
This is the layer almost no telehealth practice will reliably prescribe — most perimenopause-HRT services don’t offer it at all, and where it is offered it is often gated, dose-locked, or deflected. So it is worth being precise about what the evidence actually supports, because precision is the opposite of how this drug is usually marketed.
There is exactly one evidence-based indication for testosterone in women: postmenopausal hypoactive sexual desire dysfunction — low sexual desire that is itself distressing. That is the finding of the Global Consensus Position Statement and the accompanying meta-analysis2021, and it is the only place we make a claim. For energy, mood, cognition, muscle, or bone, the high-quality evidence shows no reliable effect — and we will not tell you otherwise.
It is prescribed off-label: there is no FDA-approved testosterone product for women, so dosing is deliberately held to the physiologic female range and confirmed by the assay described in the next section — not the male-range dosing that drives the unmonitored testosterone market. What makes this layer worth naming is access and rigor, not a longer list of promises.
Layer 03 · The metabolic layer
The GLP-1, in its proper place.
Here is the layer the category leads with, placed where the clinical reasoning actually puts it: third. GLP-1 and dual-agonist medications are among the most studied interventions in metabolic medicine, and the trial results are real.
STEP-1 · semaglutide 2.4 mg
Adults with overweight or obesity, without diabetes · 68 weeks
−14.9%22
SURMOUNT-1 · tirzepatide
Adults with obesity, highest dose · 72 weeks
−20.9%23
Mean body-weight change versus placebo. These are trial endpoints — what a study population reached under study conditions — not a number we are promising you.
What the trials also show, and what most of the category omits: a meaningful share of the weight lost on a GLP-1 alone is lean mass — muscle — not only fat24. For a body already losing lean mass to event 02, that is precisely the wrong thing to lose. It is why this layer is never prescribed alone here: it travels with protein targets and resistance training built to preserve muscle, because the goal is composition, not a smaller number on a scale.
And it is why the GLP-1 is the third layer, not the protagonist. Its real job in this protocol is narrower than the marketing suggests: it takes the metabolic noise down — the appetite shift of event 07, the visceral accumulation of event 03 — so the hormonal layer can do the deeper work. One tool, doing one job, inside a stack that does the rest.
On sourcing: this layer uses FDA-approved branded medications, with compounded semaglutide or tirzepatide reserved for cases where a clinician documents an individualized clinical need — the narrow path that remains since the national shortage that once permitted broad compounding resolved in 202528.
Four minutes, no obligation — and a clinician licensed in your state reviews what you submit before anything is prescribed.
You have probably had the visit where the labs came back “normal” and the appointment ended there — a thyroid value, a cholesterol number, and a recommendation to manage your stress. The panel below is built around a different question: not “is anything acutely wrong,” but “which of the nine events is underway, and by how much.” Each marker is here because it maps to a mechanism, not because it rounds out a page.
Metabolic markers — HbA1c, fasting glucose, and a lipid panel, read per the ADA Standards of Care27 — track the visceral and metabolic shift of event 03 and set the baseline a GLP-1 is measured against. They are the difference between adjusting a protocol to your data and adjusting it to the calendar.
The testosterone assay is where this panel separates itself, and where the most investigative members look first. Female testosterone runs at concentrations where the ordinary immunoassay is simply not accurate enough to dose against. So the panel uses total testosterone by LC-MS/MS, with SHBG, and a calculated free testosterone — the method the Endocrine Society’s androgen guideline specifies for exactly this reason26. It is the difference between a number you can prescribe the physiologic female dose against and a number that only looks like one.
Hormonal
Estradiol, FSH — for context and staging, not diagnosis
Androgens
Total testosterone (LC-MS/MS), SHBG, calculated free testosterone
Metabolic
HbA1c, fasting glucose, fasting insulin
Lipids & inflammation
Full lipid panel, hs-CRP
Thyroid & general
TSH, CBC, comprehensive metabolic panel, vitamin D
On cadence: Weightstry’s monitoring rhythm is biannual lab panels through Quest and Labcorp. That is our practice standard for following a protocol over time — a way to keep dosing tethered to your physiology — not a guideline requirement and not a diagnostic gate. Which is the right place to say what the panel does not do: it does not diagnose the transition from a single hormone level. In women 45 and older, the transition is identified clinically, from symptoms and pattern — guidance is explicit that hormone levels should not be used to diagnose menopause at that age25 — and the labs are here to calibrate care, not to grant permission to have symptoms you already know you have.
The most useful thing a practice that takes itself seriously can do on a page like this is tell you who it is not for. Here is where the protocol stops, in the same plain language as everything above.
The metabolic layer
The GLP-1 layer is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and it is used with caution in anyone with a history of pancreatitis. The common effects are gastrointestinal — nausea, reflux, altered appetite — and for most people they are most noticeable in the first weeks and ease as the dose stabilizes, typically by weeks two to four. That is the expected course; the screening exists in part to surface the histories that take this layer off the table before it is ever prescribed.
The hormonal layer
Hormone therapy has its own contraindication classes — among them a personal history of breast or other hormone-sensitive cancer, unexplained vaginal bleeding, active liver disease, and a personal history of venous thromboembolism or stroke. These are not items on a checklist to be waved past; they are the reason the protocol begins with an individualized benefit-risk discussion rather than a default prescription. The favorable window named in the protocol — under 60, or within ten years of menopause, without contraindications — is a starting frame for that conversation, not a guarantee that applies to everyone inside it.
In both directions
So, plainly: this is not for everyone. It is not for a woman whose history rules out the layers that make it work, and it is not for someone looking for a number to drop on a fixed timeline. The screening is built to find the line, honestly, in both directions — and a clinician, not a form, makes the call. We would rather tell you the protocol is not right for you than sell you a version of it that isn’t.
CertifiedLegitScript healthcare
Weightstry is LegitScript-certified. Verify
Trained in obesity medicine.
Every member is matched with a clinician and a registered dietitian.
Matched by license, specialty, and clinical fit — not by who is free.
Quest and Labcorp panels.
Lipids, hormones, metabolic and inflammatory markers drawn at intake.
Re-drawn at week 12 and week 24. Tracked, not assumed.
Named on every shipment.
State-licensed U.S. compounding pharmacy dispenses every prescription.
Active ingredient, lot, and pharmacy named on the Transparency Card.
Every protocol, reviewed.
No volume targets.
No five-minute consults.
Every protocol clinician-reviewed before dispense.
30 sources — randomized trials, cohort studies, position statements, and guidelines. Each links out to its PubMed, DOI, or issuing-body record so you can check it yourself.
- 1.Cohort study
Tepper PG, Randolph JF, McConnell DS, et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women’s Health Across the Nation (SWAN). J Clin Endocrinol Metab. 2012;97(8):2872–2880.
PMID 22659249 - 2.Review
El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227.
PMID 31568098 - 3.Cohort study
Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865.
PMID 30843880 - 4.Review
Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38(3):173–188.
PMID 28323934 - 5.Cohort study
Woods NF, Mitchell ES, Smith-DiJulio K. Cortisol levels during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Menopause. 2009;16(4):708–718.
PMID 19322116 - 6.Review
Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nat Sci Sleep. 2018;10:73–95.
PMID 29445307 - 7.Review
Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin/neurokinin B/dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211–227.
PMID 23872331 - 8.Review
Monteleone P, Mascagni G, Giannini A, et al. Symptoms of menopause — global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199–215.
PMID 29393299 - 9.Review
Vigil P, Meléndez J, Petkovic G, Del Río JP. The importance of estradiol for body weight regulation in women. Front Endocrinol (Lausanne). 2022;13:951186.
DOI 10.3389/fendo.2022.951186 - 10.Cohort study
Greendale GA, Huang M, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850–1857.
PMID 19470968 - 11.Cohort study
Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res. 2012;27(1):111–118.
PMID 21976317 - 12.Position statement
The North American Menopause Society 2022 HT Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
PMID 35797481 - 13.Guideline
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.
PMID 26444994 - 14.Randomized trial
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
PMID 17405972 - 15.Randomized trial
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221–1231.
PMID 27028912 - 16.Randomized trial
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249–260.
PMID 25069991 - 17.Randomized trial
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927–938.
PMID 28898378 - 18.Cohort study
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
PMID 17333341 - 19.Cohort study
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens — the ESTHER study. Circulation. 2007;115(7):840–845.
PMID 17309934 - 20.Position statement
Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
PMID 31498871 - 21.Meta-analysis
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766.
PMID 31353194 - 22.Randomized trial
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
PMID 33567185 - 23.Randomized trial
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
PMID 35658024 - 24.Review
Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16–27.
PMID 38937282 - 25.Guideline
National Institute for Health and Care Excellence (NICE). Menopause: identification and management. NICE guideline NG23 (do not use FSH or estradiol to diagnose menopause in women aged 45 or over). NICE. 2024.
NICE - 26.Guideline
Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal — an Endocrine Society clinical practice guideline (calculated free testosterone via total testosterone + SHBG). J Clin Endocrinol Metab. 2014;99(10):3489–3510.
DOI 10.1210/jc.2014-2260 - 27.Guideline
American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: Standards of Care in Diabetes (HbA1c, fasting glucose, lipid screening in adults with overweight/obesity and risk factors). Diabetes Care. 2025;48(Suppl 1):S27–S49.
Diabetes Care - 28.Regulatory
U.S. Food and Drug Administration. FDA clarifies policies for compounders as the national GLP-1 supply begins to stabilize (semaglutide and tirzepatide removed from the drug shortage list, 2025). FDA. 2025.
FDA - 29.Regulatory
U.S. Department of Health and Human Services / U.S. Food and Drug Administration. HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy (initiation of boxed-warning removal — cardiovascular disease, breast cancer, probable dementia — citing the WHI study’s age and formulation limitations; endometrial-cancer warning for systemic estrogen-alone products retained). FDA. 2025.
FDA - 30.Regulatory
U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products (implementation of the revised warning language). FDA. 2026.
FDA
You’ve read the evidence. The screening is the next step.
You came to check the mechanism, and the mechanism is the part this page exists to stand behind. If it holds up to the reading you’ve already done, the next move is small: a four-minute screening, reviewed by a clinician licensed in your state, that tells you whether the woman this protocol is built for is you. Not a transformation. A clear answer, and a practice that won’t make you fight for it.
Takes about 4 minutes.